Arbor Vita Corporation specializes in innovative diagnostic technologies aimed at addressing critical health challenges, particularly in the fields of infectious diseases and cancer. Their flagship product, the Onco E6™ Cervical Test, utilizes advanced proteomic diagnostics to detect cervical cancer at its earliest and most treatable stages. This test is designed for point-of-care use, providing rapid results in just over two hours without the need for refrigeration or complex processing protocols, making it accessible even in resource-limited settings. Additionally, Arbor Vita has developed a suite of COVID-19 testing solutions, including the SalivaDirect™ SARS-CoV-2 test in collaboration with Yale University, which combines accurate RT-PCR technology with painless saliva sample collection, ensuring same-day results for timely diagnosis.

The company also leverages PDZ proteomics and monoclonal antibody technology to create a range of sensitive tests for various diseases. Their pipeline includes rapid influenza detection tests, such as the AV Avantage™ A/H5N1 and A/H7N9 tests, which are designed for quick identification of specific influenza strains in clinical settings. These tests utilize proprietary PDZ technology and are FDA-authorized for emergency use, highlighting Arbor Vita's commitment to developing effective diagnostic tools that can be deployed in both advanced healthcare environments and remote locations. Through these technologies, Arbor Vita aims to improve health outcomes globally, particularly for vulnerable populations at risk for cervical cancer and infectious diseases.

United States

Arbor Vita Corporation (AVC) is a privately held company committed to making a difference by enabling early and accurate diagnosis and treatment of disease. The company has products on the market or in clinical studies to address global health challenges in the areas of HPV-induced cancer and infectious disease. AVC also has a pipeline of products in development.

Arbor Vita Corporation

Company Details